A randomized comparison of daunorubicin 90 mg/m vs 60 mg/m in AML induction: results from the UK NCRI AML17 trial in 1206 patients
نویسندگان
چکیده
Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom; Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom; Department of Haematology, University Hospital of Wales Cardiff, United Kingdom; Department of Haematology, St Bartholomew’s Hospital, West Smithfield, London United Kingdom; Department of Haematology, Rigshospitalet, Copenhagen, Denmark; Department of Haematology, Belfast City Hospital, Belfast, United Kingdom; Blackpool Victoria Hospital, Blackpool, United Kingdom; Department of Haematology, Christie Hospital, Manchester, United Kingdom; Department of Haematology, University of Odense, Odense, Denmark; Department of Haematology, Heartlands Hospital, Birmingham, United Kingdom; and Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom
منابع مشابه
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby improving survival. Escalation of the daunorubicin dose to 90 mg/m(2) has shown benefit for some patient subgroups when compared with a dose of 45 mg/m(2), and has been recommended as a standard of care. However, 60 mg/m(2) is widely used and has never been directly...
متن کاملA randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
We conducted a phase 3 randomized trial comparing 2 different doses of daunorubicin as induction chemotherapy in young adults (60 years of age or younger) with acute myeloid leukemia (AML). Of 383 patients who were analyzed, 189 received standard-dose daunorubicin (SD-DN, 45 mg/m² per day times 3 days) and 194 received high-dose daunorubicin (HD-DN, 90 mg/m² per day times 3 days) in addition to...
متن کاملIntensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?
I term survival without an apparent effect on the initial response rate. However, reports of improved disease-free surNDUCTION THERAPY for acute myeloid leukemia (AML) has been fairly standardized over the past two decades, with major controversies addressing the optimal vival attributable to intensified induction therapy need to be cautiously interpreted. Such benefit may be impossible to post...
متن کاملBenefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.
The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m(2)) improved overall survival in adults <60 years old with acute myeloid leukemia (AML); however, at initial analysis, the benefit was restricted to younger patients (<5...
متن کاملRandomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Serial studies have demonstrated that induction therapy with FLAM [flavopiridol (alvocidib) 50 mg/m(2) days 1-3, cytarabine 667 mg/m(2)/day continuous infusion days 6-8, and mitoxantrone (FLAM) 40 mg/m(2) day 9] yields complete remission rates of nearly 70% in newly diagnosed poor-risk acute myeloid leukemia. Between May 2011-July 2013, 165 newly diagnosed acute myeloid leukemia patients (age 1...
متن کامل